Annual Report of the Australian Gonococcal Surveillance Programme, 2009
DOI:
https://doi.org/10.33321/cdi.2010.34.12Keywords:
antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeaeAbstract
The Australian Gonococcal Surveillance Programme (AGSP) monitors antibiotic susceptibility testing of Neisseria gonorrhoeae isolated in all states and territories. In 2009 the in vitro susceptibility of 3,220 isolates of gonococci from public and private sector sources was determined by standardised methods. Varying antibiotic susceptibility patterns were again seen across jurisdictions and regions. Resistance to the penicillins nationally was 36% and, with the exception of the Northern Territory, ranged between 19% in Queensland and 52% in Victoria. Quinolone resistance, most at high minimal inhibitory concentration (MIC) levels, was 43% nationally (excepting the Northern Territory), and ranging from 30% in Queensland to 60% in Victoria. Decreased susceptibility to ceftriaxone (MIC 0.06 mg/L or more), was found nationally in 2% of isolates. Nationally, all isolates remained sensitive to spectinomycin. Azithromycin resistance surveillance was performed in New South Wales, Queensland, Western Australia, the Northern Territory and South Australia, and was found to be present in low numbers of gonococci with MIC values up to 16 mg/L. In larger urban centres the ratio of male to female cases was high, and rectal and pharyngeal isolates were common in men. In other centres and in rural Australia the male to female ratio of cases was lower, and most isolates were from the genital tract. Commun Dis Intell 2010;34(2):89–95.
Downloads
References
Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multi-drug and extensively drug resistant Neisseria gonorrhoea. Expert Rev Anti Infect Ther 2009;7(7);821–834.
Tapsall JW, Limnios EA, Murphy DM, Australian Gonococcal Surveillance Programme. An analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997–2006. J Antimicrob Chemother 2008;61(1):150–155.
Tapsall JW. Implications of current recommendations for third generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009;85(4):256–258.
Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, et al. Threat to cefixime treatment for gonorrhoea. Emerg Infect Dis 2007;13(8):1275–1277.
Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoea infection. Antimicrob Agents Chemother 2008;52(10):3564–3567.
Tapsall JW, Read P, Carmody C, Bourne C, Ray S, Limnios A, et al. Two cases of failed ceftriaxone treatment verified by molecular microbiological methods. J Med Microbiol 2009;58(Pt 5):683–687.
Tapsall JW. Monitoring antimicrobial resistance for public health action. Commun Dis Intell 2003,27 Suppl:S70–S74.
Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008;148(8):606–613.
Australian Gonococcal Surveillance Programme. Penicillin sensitivity of gonococci in Australia: the development of an Australian gonococcal surveillance programme. Br J Vener Dis 1984;60(4):226–230.
Australian Gonococcal Surveillance Programme. Annual report of the Australian Gonococcal Surveillance Programme, 2007. Commun Dis Intell 2008;32(2):227–231.
Tapsall J, and members of the National Neisseria Network of Australia. Antimicrobial testing and applications in the pathogenic Neisseria. In: Merlino J, ed. Antimicrobial susceptibility testing: methods and practices with an Australian perspective. Australian Society for Microbiology, Sydney, 2004. pp 175–188.
Australian Gonococcal Surveillance Programme. Use of a quality assurance scheme in a long-term multicentric study of antibiotic susceptibility of Neisseria gonorrhoeae. Genitourin Med 1990,66(1):437–444.
WHO Collaborating Centre for STD, Sydney. Rationale and applications for the current (2008) WHO panel of Neisseria gonorrhoeae for antimicrobial resistance surveillance for public health purposes, and instructions for their use. Technical document D007-0408-1#1 2008.
Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance (AMR) surveillance for public health purposes. J Antimicrob Chemother 2009;63(6):1142–1151.
The WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2007–2008. Commun Dis Intell 2010;34(1):1–7.
Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection Antimicrob Agents Chemother 2008;52(10):3564–3567.
Tapsall JW, Ray S, Limnios A. Characteristics and population dynamics of mosaic penA allele-containing Neisseria gonorrhoeae isolated in Sydney, Australia, 2007 – 2008. Antimicrob Agents Chemother 2010;54(1):554–556.
Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strain from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007;51(9):3111–3116.
Whiley DM, Goire N, Lambert SB, Ray S, Limnios EA, Nissen MD, et al. Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations P551S, P551L and G542S in the gonococcal penicillin binding protein 2. J Antimicrob Chemother 2010;28 May. PMID 20511367 [Epub ahead of print]
Newman LM, Moran JS, Workowaski KA. Update on the management of gonorrhea in Adults in the United States. Clin Infect Dis 2007;44 Suppl:S84–S101.
Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Op Infect Dis 2009;22(1):87–91.
Tapsall JW. Multi-resistant Neisseria gonorrhoea. CMAJ 2009;180(3):268–269.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2010 Communicable Diseases Intelligence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
